KR20060030575A - Pharmaceutical composition comprising the complex crude drug extract for preventing and treating hyperthyroidism - Google Patents
Pharmaceutical composition comprising the complex crude drug extract for preventing and treating hyperthyroidism Download PDFInfo
- Publication number
- KR20060030575A KR20060030575A KR1020040079405A KR20040079405A KR20060030575A KR 20060030575 A KR20060030575 A KR 20060030575A KR 1020040079405 A KR1020040079405 A KR 1020040079405A KR 20040079405 A KR20040079405 A KR 20040079405A KR 20060030575 A KR20060030575 A KR 20060030575A
- Authority
- KR
- South Korea
- Prior art keywords
- hyperthyroidism
- extract
- ginseng
- pharmaceutical composition
- white
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 40
- 206010020850 Hyperthyroidism Diseases 0.000 title claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title abstract description 7
- 229940079593 drug Drugs 0.000 title abstract description 6
- 235000008434 ginseng Nutrition 0.000 claims abstract description 21
- 239000012676 herbal extract Substances 0.000 claims abstract description 20
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 19
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 19
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 19
- 229940010454 licorice Drugs 0.000 claims abstract description 19
- 244000080767 Areca catechu Species 0.000 claims abstract description 18
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 18
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 18
- 235000006226 Areca catechu Nutrition 0.000 claims abstract description 17
- 240000002045 Guettarda speciosa Species 0.000 claims abstract description 17
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 17
- 235000006533 astragalus Nutrition 0.000 claims abstract description 17
- 241001061264 Astragalus Species 0.000 claims abstract description 16
- 210000004233 talus Anatomy 0.000 claims abstract description 16
- 235000016976 Quercus macrolepis Nutrition 0.000 claims abstract description 13
- 230000036541 health Effects 0.000 claims abstract description 12
- 235000013376 functional food Nutrition 0.000 claims abstract description 7
- 241000202807 Glycyrrhiza Species 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 235000013305 food Nutrition 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 241000411851 herbal medicine Species 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 235000015872 dietary supplement Nutrition 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims description 6
- 244000236658 Paeonia lactiflora Species 0.000 claims description 6
- 241000219492 Quercus Species 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 241000208340 Araliaceae Species 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 241000218645 Cedrus Species 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 235000008184 Piper nigrum Nutrition 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- 244000203593 Piper nigrum Species 0.000 claims 1
- 235000013614 black pepper Nutrition 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 37
- 208000024891 symptom Diseases 0.000 abstract description 10
- 230000002265 prevention Effects 0.000 abstract description 9
- 230000006793 arrhythmia Effects 0.000 abstract description 5
- 206010003119 arrhythmia Diseases 0.000 abstract description 5
- 208000001936 exophthalmos Diseases 0.000 abstract description 4
- 210000000056 organ Anatomy 0.000 abstract description 4
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 18
- 240000004371 Panax ginseng Species 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 13
- 210000001685 thyroid gland Anatomy 0.000 description 12
- 235000013361 beverage Nutrition 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 208000003532 hypothyroidism Diseases 0.000 description 5
- 230000002989 hypothyroidism Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229930182490 saponin Natural products 0.000 description 5
- 235000017709 saponins Nutrition 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000005495 thyroid hormone Substances 0.000 description 4
- 229940036555 thyroid hormone Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010018498 Goitre Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 235000002789 Panax ginseng Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 3
- -1 magnool Chemical compound 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 2
- 241000233788 Arecaceae Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HJXMNVQARNZTEE-UHFFFAOYSA-N Butylphthalide Chemical compound C1=CC=C2C(CCCC)OC(=O)C2=C1 HJXMNVQARNZTEE-UHFFFAOYSA-N 0.000 description 2
- PKRPFNXROFUNDE-LLVKDONJSA-N Byakangelicin Chemical compound O1C(=O)C=CC2=C1C(OC[C@@H](O)C(C)(C)O)=C1OC=CC1=C2OC PKRPFNXROFUNDE-LLVKDONJSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- XRDJYSVGPBJZSG-PSDLAXTLSA-N Linderenol Chemical compound C=1([C@H](O)[C@H]2C3=C)C(C)=COC=1C[C@@]2(C)[C@H]1[C@@H]3C1 XRDJYSVGPBJZSG-PSDLAXTLSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CLWOXNLVWMXBRD-QGZVFWFLSA-O Magnocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=CC=21)O)OC)C1=CC=C(O)C=C1 CLWOXNLVWMXBRD-QGZVFWFLSA-O 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- ZPIKVDODKLJKIN-NSHDSACASA-N Senkyunolide Chemical compound C1CC=CC2=C1[C@H](CCCC)OC2=O ZPIKVDODKLJKIN-NSHDSACASA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 201000003872 goiter Diseases 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 231100000544 menstrual irregularity Toxicity 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- CKMXAIVXVKGGFM-UHFFFAOYSA-N p-cumic acid Chemical compound CC(C)C1=CC=C(C(O)=O)C=C1 CKMXAIVXVKGGFM-UHFFFAOYSA-N 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229940034208 thyroxine Drugs 0.000 description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- QTAGQHZOLRFCBU-CYBMUJFWSA-N (+)-oxypeucedanin Chemical compound CC1(C)O[C@@H]1COC1=C(C=CO2)C2=CC2=C1C=CC(=O)O2 QTAGQHZOLRFCBU-CYBMUJFWSA-N 0.000 description 1
- XMGQYMWWDOXHJM-SNVBAGLBSA-N (-)-α-limonene Chemical compound CC(=C)[C@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-SNVBAGLBSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- BZQURGSQMBBPRU-DZGCQCFKSA-N (4as,8as)-3,8a-dimethyl-5-methylidene-4,4a,6,9-tetrahydrobenzo[f][1]benzofuran Chemical compound C([C@]1(C)C2)=CCC(=C)[C@@H]1CC1=C2OC=C1C BZQURGSQMBBPRU-DZGCQCFKSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FKWGZOFNSIESOX-QLFBSQMISA-N 2-[(2r,4ar,8as)-4a-methyl-8-methylidene-1,2,3,4,5,6,7,8a-octahydronaphthalen-2-yl]prop-2-en-1-ol Chemical compound C1CCC(=C)[C@@H]2C[C@H](C(=C)CO)CC[C@]21C FKWGZOFNSIESOX-QLFBSQMISA-N 0.000 description 1
- HCXVJBMSMIARIN-ZETWWWAOSA-N 24alpha-Ethyl-koprostanol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C HCXVJBMSMIARIN-ZETWWWAOSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010056519 Abdominal infection Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000332371 Abutilon x hybridum Species 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 241000544270 Angelica acutiloba Species 0.000 description 1
- 240000009300 Apodytes dimidiata Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- ORBITTMJKIGFNH-LLVKDONJSA-N Byakangelicol Chemical compound C1=2OC(=O)C=CC=2C(OC)=C2C=COC2=C1OC[C@H]1OC1(C)C ORBITTMJKIGFNH-LLVKDONJSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000548268 Citrus deliciosa Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- UXDIXFDKSPCUIX-AXFHLTTASA-N Cnidilide Chemical compound C1=CCC[C@@H]2[C@H](CCCC)OC(=O)[C@@H]21 UXDIXFDKSPCUIX-AXFHLTTASA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- YJHVMPKSUPGGPZ-UHFFFAOYSA-N Dihydro-beta-eudesmol Natural products C1CC(C(C)(C)O)CC2C(C)CCCC21C YJHVMPKSUPGGPZ-UHFFFAOYSA-N 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 241000229182 Ledebouriella seseloides Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- XRDJYSVGPBJZSG-ZXMBVREDSA-N Lindenenol Natural products Cc1coc2C[C@@]3(C)[C@@H]4C[C@@H]4C(=C)[C@@H]3[C@H](O)c12 XRDJYSVGPBJZSG-ZXMBVREDSA-N 0.000 description 1
- 241000146029 Lindera aggregata Species 0.000 description 1
- KBMSVODXFLAQNJ-DXGHHDSJSA-N Linderane Chemical compound C1=2C(C)=COC=2C\C(C)=C\CC[C@@]23C(=O)O[C@@H]1[C@@H]2O3 KBMSVODXFLAQNJ-DXGHHDSJSA-N 0.000 description 1
- KBMSVODXFLAQNJ-ZEBDJQDSSA-N Linderane Natural products O=C1O[C@@H]2[C@@H]3O[C@]13CC/C=C(/C)\Cc1occ(C)c21 KBMSVODXFLAQNJ-ZEBDJQDSSA-N 0.000 description 1
- BZQURGSQMBBPRU-ZFWWWQNUSA-N Lindestrene Natural products C=C1[C@H]2[C@@](C)(C=CC1)Cc1occ(C)c1C2 BZQURGSQMBBPRU-ZFWWWQNUSA-N 0.000 description 1
- 241001673966 Magnolia officinalis Species 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- UPJFTVFLSIQQAV-KOLCDFICSA-N Neocnidilide Chemical compound C1CC[C@H]2[C@H](CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-KOLCDFICSA-N 0.000 description 1
- UPJFTVFLSIQQAV-UHFFFAOYSA-N Neocnidilide Natural products C1CCC2C(CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- QTAGQHZOLRFCBU-UHFFFAOYSA-N Oxypeucadanin Natural products CC1(C)OC1COC1=C(C=CO2)C2=CC2=C1C=CC(=O)O2 QTAGQHZOLRFCBU-UHFFFAOYSA-N 0.000 description 1
- NUCBCBCPICFGMZ-UHFFFAOYSA-N Oxypeucedanin Natural products CC1(C)OC1COC1=CC(=O)OC2=C1C=C1C=COC1=C2 NUCBCBCPICFGMZ-UHFFFAOYSA-N 0.000 description 1
- MWEVYJRFLDKUCW-UHFFFAOYSA-N Oxypeucedonin-hydrat Natural products CC(C)(O)C(O)Cc1c2C=CC(=O)Oc2cc3occc13 MWEVYJRFLDKUCW-UHFFFAOYSA-N 0.000 description 1
- 241000124501 Paeonia obovata var. japonica Species 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 235000004348 Perilla frutescens Nutrition 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 240000008154 Piper betle Species 0.000 description 1
- 235000008180 Piper betle Nutrition 0.000 description 1
- 240000003889 Piper guineense Species 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000021129 Postpartum disease Diseases 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- CBSRFDQDBGGSEA-UHFFFAOYSA-N Selinene Natural products CC(=C1CCC2(C)CCCC(=C)C2(C)C1)C CBSRFDQDBGGSEA-UHFFFAOYSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010043784 Thyroiditis subacute Diseases 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 241001464837 Viridiplantae Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000012876 acute enteritis Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 1
- IPZIYGAXCZTOMH-UHFFFAOYSA-N alpha-eudesmol Natural products CC1=CCCC2CCC(CC12)C(C)(C)O IPZIYGAXCZTOMH-UHFFFAOYSA-N 0.000 description 1
- UZFLPKAIBPNNCA-BQYQJAHWSA-N alpha-ionone Chemical compound CC(=O)\C=C\C1C(C)=CCCC1(C)C UZFLPKAIBPNNCA-BQYQJAHWSA-N 0.000 description 1
- UZFLPKAIBPNNCA-UHFFFAOYSA-N alpha-ionone Natural products CC(=O)C=CC1C(C)=CCCC1(C)C UZFLPKAIBPNNCA-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- JZVFJDZBLUFKCA-UTQQLQBSSA-N alpha-spinasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2C3=CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C JZVFJDZBLUFKCA-UTQQLQBSSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- XFSVWZZZIUIYHP-UHFFFAOYSA-N beta-Eudesmol Natural products CC(C)(O)C1CCC2CCCC(=C)C2C1 XFSVWZZZIUIYHP-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- BOPIMTNSYWYZOC-VNHYZAJKSA-N beta-eudesmol Chemical compound C1CCC(=C)[C@@H]2C[C@H](C(C)(O)C)CC[C@]21C BOPIMTNSYWYZOC-VNHYZAJKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- PKRPFNXROFUNDE-UHFFFAOYSA-N biac-angelicin Natural products O1C(=O)C=CC2=C1C(OCC(O)C(C)(C)O)=C1OC=CC1=C2OC PKRPFNXROFUNDE-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229950005197 butylphthalide Drugs 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229930006739 camphene Natural products 0.000 description 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- UXDIXFDKSPCUIX-UHFFFAOYSA-N condilide Natural products C1=CCCC2C(CCCC)OC(=O)C21 UXDIXFDKSPCUIX-UHFFFAOYSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229930016889 costol Natural products 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- FRBORWNVTCITAQ-UHFFFAOYSA-N ferulin Natural products C1=C2C(C)=CC(=O)C2=C(C)CC2OC(=O)C(C)C21 FRBORWNVTCITAQ-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- ITRHZWKEZJYJQO-UHFFFAOYSA-N gamma-costol Natural products C1C(C(=C)CO)CCC2(C)CCCC(C)=C21 ITRHZWKEZJYJQO-UHFFFAOYSA-N 0.000 description 1
- WWULHQLTPGKDAM-UHFFFAOYSA-N gamma-eudesmol Natural products CC(C)C1CC(O)C2(C)CCCC(=C2C1)C WWULHQLTPGKDAM-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 201000008494 nodular goiter Diseases 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- HRWVKZXRZVVBLP-UHFFFAOYSA-N oxypeucedanin hydrate Natural products CC(C)(O)C(O)CCc1c2C=CC(=O)Oc2cc3occc13 HRWVKZXRZVVBLP-UHFFFAOYSA-N 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- VPQBJIRQUUEAFC-UHFFFAOYSA-N selinene Natural products C1CC=C(C)C2CC(C(C)C)CCC21C VPQBJIRQUUEAFC-UHFFFAOYSA-N 0.000 description 1
- 150000003598 selinene derivatives Chemical class 0.000 description 1
- 229930183325 senkyunolide Natural products 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 201000007497 subacute thyroiditis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000000534 thyroid cartilage Anatomy 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 생약추출물을 함유하는 갑상선기능 항진증 개선용 조성물에 관한 것으로, 보다 상세하게는 소엽, 인삼, 황기, 당귀, 천궁, 계지, 후박, 백지, 방풍, 오약, 빈랑, 백작약, 지각, 목향, 감초 및 길경 추출물로 구성된 복합 생약 추출물을 함유하는 갑상선 기능 항진증의 예방 및 치료를 위한 약학조성물에 관한 것이다. 본 발명의 조성물은 갑상선 기능의 항진에 의해 유발된 안구돌출증상, 갑상선 비대, 부정맥 등의 증상이 완화되면서도 인체에 안정하기 때문에 갑상선 기능 항진증의 예방 및 치료를 위한 의약품 및 건강기능식품에 유용하게 사용될 수 있다.
The present invention relates to a composition for improving hyperthyroidism containing herbal extracts, and more specifically, lobular, ginseng, Astragalus, Angelica, celestial organ, gyeji, thick, white paper, windproof, oak, betel nut, white peach, crust, mokyang, The present invention relates to a pharmaceutical composition for the prevention and treatment of hyperthyroidism, which contains a complex herbal extract consisting of licorice and gilyeong extract. The composition of the present invention is useful in medicines and health functional foods for the prevention and treatment of hyperthyroidism because it is stable to the human body while alleviating symptoms such as exophthalmos, hyperthyroidism, arrhythmia and the like caused by hyperthyroidism Can be.
갑상선기능항진, 소엽, 약학 조성물Hyperthyroidism, lobules, pharmaceutical compositions
Description
소엽, 인삼, 황기, 당귀, 천궁, 계지, 후박, 백지, 방풍, 오약, 빈랑, 백작약, 지각, 목향, 감초 및 길경 추출물로 구성된 복합 생약 추출물을 함유하는 갑상선 기능 항진증의 예방 및 치료를 위한 약학조성물에 관한 것이다.
Pharmaceutics for the prevention and treatment of hyperthyroidism containing complex herbal extracts consisting of lobular, ginseng, Astragalus, Angelica, celestial, gyeji, hoobak, white paper, windproof, oak, betel nut, white peony, crust, cedar, licorice and gil dynasty It relates to a composition.
갑상선은 후두(喉頭)의 전면 갑상연골(甲狀軟骨) 아래에 있는 내분비선으로, 주요 기능은 갑성선 호르몬인 티록신(thyroxine)의 생산이다. 티록신은 탄수화물, 단백질, 지방의 대사조절에 관여하고 있으며, 성장호르몬 등의 기능을 강화시키기도 한다. The thyroid gland is an endocrine gland below the anterior thyroid cartilage of the larynx. Its main function is the production of thyroxine, the thyroid hormone. Thyroxine is involved in the regulation of carbohydrates, proteins and fats, and also enhances the function of growth hormone.
갑상선 기능 항진증(hyperthyroidism)은 갑상선의 기능이 병적으로 증가하여 호르몬이 과다하게 분비되는 질병으로서, 갑상선 자체에서 갑상선 호르몬을 과도하게 생산하여 혈액 중 갑상선 호르몬의 농도가 상승함에 따라 특유의 임상 증세나 생화학적인 변화를 나타내는 것을 말한다. 20 ~ 50 대의 여성에서 많이 발생하며, 환자의 5%는 소아이다. 그 원인은 자가면역질환인 바제도병(또는 그레이브스병)에 의한 경우가 대부분이지만, 이밖에 중독성 결절성 갑상선종(플러머병), 뇌하수체의 갑상선 자극호르몬 분비선종, 갑상선암, 무통성 갑상선염이나 아급성 갑상선염의 초기에도 나타난다. 혈액 속에 갑상선호르몬이 많아지면 물질대사가 항진되므로 몸이 더워지고 외부온도에 대해 예민해진다. 따라서 더위를 참지 못하고 땀을 많이 흘리며 식욕은 증가하는데도 체중이 계속 줄어 대개 1 ~ 2개월 사이에 3 ~ 4kg 씩 빠진다. 맥박이 빨라지고 가슴이 두근거리며 부정맥이 생겨 맥이 불규칙해지기도 한다. 피부는 따뜻하고 습해지며, 목에 이물감이나 통증을 느끼기도 한다. 또한, 신경이 예민해지고 불안해 하며 늘 피로를 느낀다. 잠을 잘 못자고, 손이 떨리며, 팔다리의 힘이 약해지고 심하면 마비증세가 나타난다. 생리주기가 불규칙해지며, 그 양도 감소하거나 심지어 생리가 중단되기도 한다. 한편, 갑상선이 있는 목 앞쪽이 튀어나오거나 심한 경우 안구가 튀어나오는 수도 있다.Hyperthyroidism is a disease in which the function of the thyroid gland is increased due to a pathological increase in the function of the thyroid gland.The thyroid gland produces excessive amounts of thyroid hormone, which increases the concentration of thyroid hormone in the blood. It refers to a change in nature. Occurs in women in their 20s and 50s, with 5% of children being children. The cause is most often due to autoimmune disease, Bajes 'disease (or Graves' disease), but in addition to addictive nodular goiter (plumer's disease), thyroid-stimulating hormone gland of the pituitary gland, thyroid cancer, painless thyroiditis or subacute thyroiditis Appears on The more thyroid hormones in the blood, the greater the metabolism, which makes the body warmer and more sensitive to external temperatures. Therefore, you can not stand the heat, sweat a lot, and the appetite increases, but the weight continues to decrease, usually between 1 to 2 months by 3 to 4kg. The pulse is faster, the chest is pounding, and an arrhythmia occurs, which causes irregular pulses. Your skin becomes warm and moist, and you may feel foreign body pain or pain in your neck. In addition, the nerves are nervous, nervous, and always feel tired. If you can't sleep well, your hands are trembling, your limbs are weak, and you are paralyzed. Menstrual cycles may become irregular, the amount may decrease, or even menstruation may stop. On the other hand, the front of the neck with the thyroid gland may protrude or, in severe cases, the eye may protrude.
이러한, 갑상선 기능항진증의 치료를 위해 방사성 요오드를 사용하여 갑상선 기능을 억제하거나 심한 경우 외과적 수술을 통해 갑상선을 제거하게 된다.
For the treatment of hyperthyroidism, radioactive iodine is used to suppress thyroid function or, in severe cases, to remove the thyroid gland through surgical surgery.
꿀풀과(Labiatae)의 일년생 초본인 소엽(蘇葉, Perilla frutescens BRITT. ; 차조기)은 한방에서는 잎을 소엽(蘇葉), 종자를 자소자(紫蘇子)라고 하며, 소엽 전체의 정유(精油)성분에는 페릴알데하이드 약 55%, ℓ-리몬넨(ℓ-limonene) 20-30% 및 α-피넨(pinene) 소량 외에 아르기닌, 쿠민산(cumic acid), 시아니딘-3-(6-p-쿠 마로일-β-D-글루코사이드)-5-β-D-글루코사이드를 함유하고 있고, 잎의 정제된 유지성분에는 이소에고마 케톤(isoegoma ketone)등이 함유되어 있다. 발한, 진해, 건위, 이뇨, 진정 및 진통제로 사용한다. 소두(蘇頭)는 소엽의 뿌리 및 뿌리에 가까운 부분의 오래된 줄기로, 통풍을 물리치고, 발한, 거담에 효과가 있으며 기(氣)를 내리는데 효과가 있으며, 현기증과 신체의 통증 및 코막힘, 콧물을 치료하는데 효과가 있다(정보섭 및 신민교 도해 향약(생약)대사전, 영림사, pp855-856, 1998). Perilla frutescens BRITT (perilla frutes), an annual herb of Lacaceae, is called foliar and seed in medicinal plants, and essential oil of the entire lobular. Ingredients include arginine, cumic acid, cyanidin-3- (6-p-cue, in addition to about 55% perylaldehyde, 20-30% l-limonene and small amounts of α-pinene. Maroyl- [beta] -D-glucoside) -5- [beta] -D-glucoside, and the refined fat and oil component of the leaf contains isoeegoma ketone. Used as a sweat, antitussive, dry, diuretic, soothing and analgesic. Small stems are old stems of the lobules and the roots of the lobules, which are effective in combating gout, sweating and expectoration, lowering the qi, dizziness, body pain and nasal congestion, It is effective in treating a runny nose (Information and Sinmin-kyo Ilbo Herbal Medicine Dictionary, Younglimsa, pp855-856, 1998).
인삼(Panax ginseng)은 식물 분류학상 오가과(Araliaceae) 인삼속에 속하는 다년생 숙근초로서 예로부터 귀중한 보약으로 사용되어오고 있고, 지금까지 많은 약리실험을 통해 스트레스에 대한 생체의 비특이적 저항성을 강화시키고 항산성 작용을 갖고 있음이 밝혀졌다. 인상의 주요성분인 사포닌(saponin)은 13종 이상의 사포닌 혼합물로서, 여러 생리활성이 있다. 그 효능으로는 대뇌피질의 흥분작용 및 억제과정을 강화시키는 작용, 항 스트레스효과, 고혈압 증상의 개선, 인슐린 작용증강, 알록산(alloxan) 당뇨마우스에서의 혈당강하효과, 흰쥐의 간 RNA 합성, 단백질 합성, 당 및 지질대사 촉진효과, 항암효과 등이 있는 것으로 알려져 있다(정보섭 및 신민교, 향약대사전, 영림사, pp439-442, 1998).Panax ginseng (Panax ginseng) is a perennial plant root of the genus Araliaceae in the plant taxonomy and has been used as a valuable remedy since ancient times. Through many pharmacological experiments, Panax ginseng enhances the nonspecific resistance of the body to stress and its anti-acid action. Turned out to have. Saponin, the main ingredient of the impression, is a mixture of 13 or more saponins and has various biological activities. Its effects include strengthening cerebral cortex excitability and suppression process, antistress effect, improvement of hypertension symptoms, insulin action, hypoglycemic effect in alloxan diabetic mouse, liver RNA synthesis in rats, protein Synthesis, sugar and lipid metabolism promoting effect, and anti-cancer effect is known (Information and Shin Mingyo, medicinal herb, Yeonglimsa, pp439-442, 1998).
황기(Astragalus membranaceus (FISCH.) BGE)는 콩과의 다년생 초본으로, 뿌리를 건조시켜 사용하고, 글루쿠론(glucuron)산, 단백질, 수종의 아미노산, 엽산 등이 유효성분으로 함유되어 있다. 황기는 강심작용이 있으며, 관상동맥 또는 전신의 말초혈관을 확장시켜 혈압 강하 및 이뇨작용을 가진다. 또한, 간장을 보호하여 간 글리코겐의 감소를 막는 작용, 진정작용, 자궁수축, 혈당치의 감소를 유도하는 효과가 있다(정 보섭 및 신 민교; 향약대사전, 영림사, pp662-664, 1998). Astragalus membranaceus (FISCH.) BGE is a perennial herb, used to dry roots, and contains glucuronic acid, proteins, several amino acids, and folic acid as active ingredients. Astragalus has a cardiovascular effect, dilates coronary or systemic peripheral blood vessels, lowers blood pressure and diuretic. In addition, it protects the liver and has the effect of preventing hepatic glycogen reduction, sedation, uterine contraction, and blood sugar reduction (Jung Bo-seop and Shin, Min-Kyo; Hyang-Jung-Dae, Yeonglimsa, pp662-664, 1998).
당귀(Angelica acutiloba (S. et Z.) KITAGAWA)는 국내에서 재배되는 귀화 식물이며, 일본이 원산지인 여러해살이풀로 높이 60 내지 90cm이고, 꽃은 흰색으로 8~9월에 가지 끝에 달리며, 열매는 편평한 긴 타원형이고 가장자리에 좁은 날개가 있다. 뿌리를 당귀라고 하는데, 보혈의 효능이 있으므로 얼굴에 핏기가 없고 현기증이 자주 나며 눈과 입술에 윤기가 없는 사람에게 효능이 있다고 알려져 있다. 몸이 허약하여 오는 두통, 여성들의 월경 조절 효능이 뛰어나므로 산전이나 산후의 여러 질병에 자주 사용되며, 월경불순, 복통을 치료한다. 위장의 기능이 약해서 오는 변비 치료에 효과가 있다(배 기환 저, 민간요법과 한방요법에 따른 건강지침서 원색도감, pp102-103, 2003).Angelica (Angelica acutiloba (S. et Z.) KITAGAWA) is a naturalized plants that are grown in Korea, Japan and the origin of 60 to 90cm in height perennial, flowers hangs on the branches at the end of August to September in white, Fruits Are long oval flat and have narrow wings at the edges. The root is called Angelica, which has the effect of blood, so there is no blood on the face, dizziness is frequent, and it is known to be effective for people who have no gloss on eyes and lips. Headache is weak body, women's menstrual control effect is excellent, so it is often used in various prenatal and postpartum diseases, and it treats menstrual irregularities and abdominal pain. It is effective in treating constipation due to weak gastrointestinal function (Bae Ki-hwan), color guidebook for health guidelines according to folk remedies and herbal remedies, pp102-103, 2003.
천궁(川芎)은 산형과(umbelliferae)에 속한 다년생 초본으로, 한방에서는 그 뿌리줄기를 건조하여 두통이나 불임,월경불순, 빈혈, 강장, 냉증과 같은 부인과 질환에 주로 사용되고 있다. 천궁의 화학 성분으로는 프탈라이드계(phthalide) 성분인 크니딜라이드(cnidilide), 네오크니딜라이드(neocnidilide), 리구스틸라이드(ligustilide), 부틸프탈라이드(butylphthalide), 센큐놀라이드(senkyunolide) 등이 함유되어 있다(Fuzita M. 및 Kobayashi M.; Chem. Pharm. Bull., 35(4), pp1427-1433, 1987). Cheongung (川芎) is a perennial herb belonging to umbelliferae, and in oriental medicine, its root stem is dried and is mainly used for gynecological diseases such as headache, infertility, menstrual irregularity, anemia, tonic, and coldness. The chemical components of the horoscope include phthalide-based compounds such as cnidilide, neocnidilide, ligustilide, butylphthalide and senkyunolide. (Fuzita M. and Kobayashi M . ; Chem. Pharm. Bull., 35 (4), pp1427-1433, 1987).
계지(Cinnamomi Ramulus)는 육계나무(Cinnamomun loureirii NEES)의 햇가지를 15㎝ 정도의 길이로 잘라서 햇볕에 말린 것을 의미하며, 한약재로 사용된다. 맛은 신(辛)하고 성질은 온(溫)한 약으로 기표(肌表)의 풍한(風寒)을 발산하며, 사지 에 도달하여 경락(經絡)을 선통(宣統)게 하고 관절(關節)을 이(利)하게 한다. 온통(溫痛)의 작용은 활혈통경(活血通經)하고 산한지통(散寒之痛)하는 효능이 있어 외감풍한(外感風寒)과 풍한습비(風寒濕痺) 및 경폐(經閉), 통경(通經) 등의 증상을 치료하는데 사용된다. 또한 계지에는 알칼로이드(alkaloid) 0.07%, 사포닌(saponin) 2.06%, 탄닌(tannin) 2.51% 및 정유가 함유되어 있다(정 보섭 및 신 민교, 향약대사전, 영림사, p455 ,1998). Ginji (Cinnamomi Ramulus) means that the branches of the broiler tree ( Cinnamomun loureirii NEES) are cut to 15cm in length and dried in the sun, and is used as a herbal medicine. Taste is sour and gentle in nature. It radiates the richness of the mark, and reaches the limbs, making meridians more painful and articulating. Make it happen. The action of all over the body has the effect of active blood circulation and acidic pain, so it has an external feeling of cold (풍 感 痛), abundant humidity ratio (寒濕 痺) and menopause (經 閉), It is used to treat symptoms such as pain and pain. It also contains 0.07% alkaloids, 2.06% saponins, 2.51% tannins, and essential oils (Jung Bo-seop and Shin-Kyomin, Pharmacology, Yeonglimsa, p455,1998).
후박(후박)은 목련과(Magnoliaceae)에 속하는 다년생 초본인 마그놀리아 오피시날리스(Magnolia officinalis REHD. et WILS), 및 동속 근연종의 수피를 건조한 것으로서, 행기조습(行氣燥濕), 항역평천(降逆平喘)의 효능을 가진다고 알려져 있다. 후박에는 β-유데스몰(eudesmol), 마그놀올(magnolol), 호노키올(honokiol), 마그노쿠라린(magnocurarine), 탄닌(tannin) 등이 있으며, 한방에서는 건위소화, 사하, 진해 거담제로서 방향성 건위 및 복통, 복부팽만, 급성장염, 해수(咳嗽) 등의 치료에 효과가 있다(정 보섭 및 신 민교, 향약대사전, 영림사, pp469-471,1998).Hupak is a dried perennial herb, Magnolia officinalis REHD. Et WILS, and the related bark of the genus Magnoliaceae . It is known to have the efficacy of anti-retrograde (降 逆 平喘). Thickening includes β-eudesmol, magnool, magnolol, honokiol, magnocurarine, tannin, etc. And it is effective in the treatment of abdominal pain, bloating, acute enteritis, seawater, etc. (Bo Bo-seop and Shin Min-gyo, Hyangjeomsa, Yeonglimsa, pp469-471,1998).
백지(白芷)는 다년생 초본인 구릿대 및 동속 근록식물의 뿌리를 캐어 잔뿌리는 제거하고 햇볕에 말려 사용하며, 바이약-안젤리신(byak-angelicin), 바이약-안젤리콜(byak-angelicol), 옥시퓨세다닌(oxypeucedanin), 토린(torin), 이소임페라토린(isoimperatorin),펠로프테린(phellopterin) 등의 성분을 가지고 있다. 대장균, 콜레라균 등에 대한 항균작용을 지니며, 기타 동물의 혈관의 연동중추, 호흡중추, 미주신경 및 척수에 대하여 흥분작용이 있어서 혈압의 상승, 저압을 느리게 하 고 심호흡을 하게 하므로, 두통, 치통, 비연(鼻淵), 한습(寒濕)복통, 피부건조를 치료하는 효과가 있다(정 보섭 및 신 민교, 향약대사전, 영림사, pp409-410, 1998).White paper removes the roots of perennial herbaceous copper roots and similar green plants, and removes the roots of roots and dries them in the sun. Byak-angelicin, byak-angelicol, and oxy It has ingredients such as oxypeucedanin, torin, torsoimperatorin, and pepopteropterin. It has antibacterial action against E. coli, cholera, etc., and it has an excitement effect on the peristaltic, respiratory, vagus nerve and spinal cord of blood vessels of other animals, so that it raises blood pressure, slows down low pressure and takes deep breaths. It is effective in treating non-yeon, damp-abdominal pain, and skin dryness (Bo Bo-seop and Shin Min-kyo, Hyang-dae metabolism, Younglimsa, pp409-410, 1998).
방풍(Ledebouriella seseloides WOLF.)은 미나리과(Umbelliferae)에 속하는 3년생 초본인 방풍, 갯기름 나무의 뿌리를 햇볕에 말려서 사용하며, 방풍에는 정유, 만니톨(mannitol), 고미배당체(苦味配糖體) 등이 함유되어 있고, 발한, 해역, 진통, 이뇨작용이 있다(정 보섭 및 신 민교, 향약대사전, 영림사, p428, 1998).Windproof ( Ledebouriella seseloides WOLF.) Is used to dry the roots of the three-year-old herb, Umbelliferae. , Sweating, sea area, analgesic, diuretic (Bo Bo-seop and Shin Mingyo, Hyangjeomsa, Yeonglimsa, p428, 1998).
오약(烏藥)은 녹나무과(Lauraceae)에 속하는 오약나무(Lindera Stryc- hnifolia)의 뿌리를 말린 것으로, 린데란(linderane), 린데렌(linderene), 린데레놀(linderenol), 린데스트렌(lindestrene) 등이 함유되어 있다. 방향성 건위, 진통, 진경약으로서 복통, 복염, 하리, 신경성 위염, 구토, 빈뇨, 월경통 등의 치료에 효능이 있다(Hu, S.L., Chi, Q., Zhao, Z, Heilongjiang Science & Technology Press, Harbin, pp331-333, 1989).Spilled dried roots of Lindera Stryc-hnifolia belonging to the family Lauraceae. Linderane, Linderene , Linderenol, Lindestrene Etc. are contained. Aromatic stomach, analgesic, analgesic, effective in the treatment of abdominal pain, abdominal infection, hari, nervous gastritis, vomiting, frequent urination, dysmenorrhea (Hu, SL, Chi, Q., Zhao, Z, Heilongjiang Science & Technology Press, Harbin) , pp 331-333, 1989).
빈랑(Areca catechu L.)은 종려과(Palmae)에 속하는 빈랑의 종자로 햇볕에 말려서 사용하며, 알칼로이드 성분이 0.3-0.6%, 축합형 탄닌이 15%, 지방 14% 및 아레카 레드가 함유되어 있다. 살충(殺蟲), 파적(破積), 하기(下氣), 행수(行水)의 효능이 있다(정 보섭 및 신 민교, 향약대사전, 영림사, pp272-274, 1998). Betel nut ( Areca catechu L.) is a seed of the betel nut belonging to the palm family (Palmae) is used in the sun dried, contains 0.3-0.6% alkaloids, 15% condensed tannins, 14% fat and Areca red. It is effective in insecticidal, loquat, Hagi, and Haengsu (Jung Bo-seop and Shin Mingyo, Hyangjedae, Yeonglimsa, pp272-274, 1998).
백작약(Paeonia japonica (MAKINO) MIYABE et TAKEDA)은 함박꽃의 뿌리로 다년생 초본으로 높이가 50cm이내이고, 꽃은 5~6월에 핀다. 가을에 캐어 근경 및 수염뿌리를 제거하고 깨끗이 씻어 말려서 사용한다. 뿌리에는 파에니플로린 (paeoniflorin)이 1.8~7.3% 함유되어 있고, 뿌리껍질에는 1~1.1%가 함유되어 있다. 이 외에도 정유, 지방유, 수지, 탄닌(tannin), 당, 점액질 등이 함유되어 있다. 백작약의 파에니플로린은 진정진통작용, 항염작용 이외에도 억균작용, 월경통 등에 효과가 있다(정 보섭, 신 민교, 향약대사전, 영림사, pp524-525, 1998). Paeonia japonica (MAKINO) MIYABE et TAKEDA is a perennial herb that is less than 50cm tall and blooms in May-June. In autumn, care roots and beard roots are removed, washed and dried. Root contains 1.8 ~ 7.3% of paeoniflorin and root bark contains 1 ~ 1.1%. In addition, it contains essential oils, fatty oils, resins, tannins, sugars, and mucus. Paeniflorin of Count is effective in antifungal and menstrual pain in addition to soothing analgesic and anti-inflammatory effects (Bo Bo-seop, Shin Min-gyo, Hyangjeomsa, Younglimsa, pp524-525, 1998)
지각(枳殼)은 운향(Rutaceae)에 속하는 탱자나무, 광귤나무의 성숙하기 직전의 미성숙 과실로서, 건조하여 사용한다(정보섭, 신민교저, 향약대사전, 영림사, 1998, p.793).Crust is an immature fruit just before the maturation of Tangerine and Tangerine trees belonging to the Rutaceae. It is dried and used.
목향(木香)은 국화과(Compositae)에 속하는 다년생 초본인 운목향 및 동속 근록식물의 뿌리를 햇볕에 말려서 사용하며, 아플로탁센(aplotaxene), α-이오논(ionone), β-셀리넨(selinene), 코스톨(costol), 캠펜(camphene) 등의 정유성분 및 스티그마스테롤(stigmasterol), 이눌린(inulin) 등을 함유하고 있다. 위장기의 복통을 완화시키고, 혈압을 가하시키며, 말초혈관을 확장하여 심장을 억제 하는 작용과 관련이 있으며, 항균작용이 있다(정 보섭 및 신 민교, 향약대사전, 영림사, pp1066-1068, 1998).Mok-hyang is a perennial herb that is a perennial herb that is used to dry the roots of the perennial herb, and the same roots of plants in the sun, and aflotaxene, α-ionone, and β-celinene ( essential oils such as selinene, costol and camphene, and stigmasterol, inulin, and the like. It is associated with the action of relieving stomach pain in the gastrointestinal tract, increasing blood pressure, inhibiting the heart by expanding peripheral blood vessels, and has antibacterial effects (Jung Bo-seop and Shin Min-kyo, Ph.D., Yeonglimsa, pp1066-1068, 1998 ).
감초(甘草, Glycyrrhiza uralensis FISCH.)는 콩과의 다년생 초본으로, 감초는 한방에서 모든 약재와 조화를 이루면서 효능을 증가시킬 뿐만 아니라 완화, 진통약으로 각종 동통 및 급박증상을 완화하는데 내복용 또는 외용으로 사용되고, 그 자체가 독의 중화작용과 같은 약성이 있다. 예를 들면, 감초는 간장을 보호하고 간기능을 원활하게 하여 피로를 조절하는 약효가 있어서, 감초를 복용하면 그 해독작용에 의해 간의 부담이 경감된다. 식물의 뿌리 및 근경에 트리터펜(triterpene)계 사포닌(saponin), 글리시리진(glycyrrhizin)이 함유되어 있어 약물 중독, 음식물 중독, 체내대사물의 중독 뿐 만 아니라 세균독소에 대한 모든 해독작용을 가지며, 항이뇨작용 및 갑상선피지호르몬양의 조절 작용이 있다. 감초는 항염증과 항알레르기반응작용을 보이며, 아세틸콜린에 대해 길항하는 작용을 나타내며, 아드레날린의 강심작용을 증강시키는 효과가 있다(정보섭 및 신민교 도해 향약(생약)대사전, 영림사, pp684-687, 1998).Licorice ( Glycyrrhiza uralensis FISCH.) Is a perennial herb, which is a herbaceous perennial herb. It is used as a drug, and itself has a weakness such as neutralization of poison. For example, licorice has the effect of protecting the liver and smoothing the liver and regulating fatigue, and taking licorice reduces the burden on the liver by its detoxification. Triterpene-based saponins and glycyrrhizin are contained in the roots and roots of plants, so they have all detoxification effects on bacterial toxins as well as drug addiction, food poisoning, and metabolism in the body. There is a function and regulation of thyroid sebum hormone. Licorice has anti-inflammatory and anti-allergic reactions, antagonistic action against acetylcholine, and a potent effect of adrenaline stimulation. 1998).
길경(桔梗)은 초롱꽃과(Companulaceae)에 속하는 다년생 초본인 도라지의 뿌리를 햇볕에 말려서 사용하며, 사포닌을 함유하며, 플라티코디제닌, 글루코스, α-스피나스테롤(spinasterol), 베툴린(betulin), 이눌린(inulin) 등을 함유하고 있다. 길경은 기관의 분비를 촉진하는 작용이 강하고 담액을 적게 하므로 좋은 거담작용이 있다(정 보섭 및 신 민교, 향약대사전, 영림사, p1089, 1998).Gil-Gi is used to dry the roots of perennial herbaceous bellflower, which belongs to the Companulaceae, in the sun, contains saponins, platydigenin, glucose, α-spinasterol, and betulin. ), Inulin and the like. Gilkyung has a good expectorant action because it promotes the secretion of organs and reduces the amount of bile (Jung Bo-seop and Shin Min-kyo, Hyangjeomsa, Yeonglimsa, p1089, 1998).
상기와 같이, 오랜 옛날부터 한방과 민간에서 특별한 독성이나 부작용 없이 사용되어온 소엽, 인삼, 황기, 당귀, 천궁, 계지, 후박, 백지, 방풍, 오약, 빈랑, 백작약, 지각, 목향, 감초 및 길경 등에 대해서는 그 동안 과학적으로도 각각의 효능 및 독성에 대한 많은 연구가 이루어져 왔다. 그러나, 상기 생약 추출물을 함유하는 갑상선 기능항진증 개선용 조성물에 대해서는 어떠한 연구 문헌이나 기타 자료가 없을 뿐만 아니라 연구 자체도 이루어지지 않은 실정이다.
As mentioned above, lobules, ginseng, Astragalus, Angelica, Cheongung, Gyeji, Hakbak, White Paper, Windproof, Yakja, Betel, Peony, Crust, Mokji, Licorice and Gilkyong have been used in traditional medicine and folk medicine without special toxicity or side effects. In the meantime, many studies on the efficacy and toxicity of each have been done scientifically. However, there is no research literature or other data about the composition for improving hyperthyroidism containing the herbal extract as well as the study itself.
이에 본 발명자들은 갑상선 기능항진을 개선하는 한방방제를 탐색하고 의약품으로서의 이용성을 높이려는 연구의 일환으로서, 상기의 소엽, 인삼, 황기, 당 귀, 천궁, 계지, 후박, 백지, 방풍, 오약, 빈랑, 백작약, 지각, 목향, 감초 및 길경을 함유하는 한방방제인 십육미유기음 추출물이 갑상선 기능 항진증에 유발된 안구돌출증상, 갑상선비대, 부정맥 등의 증상의 완화에 우수한 효과를 나타내는 것을 확인하고 본 발명을 완성하였다.
Therefore, the present inventors have searched for herbal medicines to improve thyroid dysfunction and improve the usability as medicines. The above-mentioned lobules, ginseng, Astragalus, Angelica, Cheongung, Gyeji, hakbak, white paper, windproof, oak, betel nut It is confirmed that the herb extract of sixteen organic extracts containing herbal medicine, earl, crust, neck, licorice and gilyeong show excellent effects on the relief of symptoms such as ocular prolapse, hyperthyroidism and arrhythmia caused by hyperthyroidism. Was completed.
본 발명의 목적은 소엽, 인삼, 황기, 당귀, 천궁, 계지, 후박, 백지, 방풍, 오약, 빈랑, 백작약, 지각, 목향, 감초 및 길경으로 구성된 복합 생약 추출물을 유효성분으로 함유하는 갑상선 기능 항진증의 예방 또는 치료용 약학 조성물 및 건강기능식품을 제공하는 것이다.
An object of the present invention is a hyperthyroidism containing a complex herbal extract consisting of lobule, ginseng, Astragalus, Angelica, celcius, lanceolate, vulgaris, white paper, windproof, oak, betel nut, baekjak, crust, cedar, licorice and Giltyeong as an active ingredient. It provides a pharmaceutical composition and health functional food for the prevention or treatment of.
상기 목적을 달성하기 위하여, 본 발명은 소엽, 인삼, 황기, 당귀, 천궁, 계지, 후박, 백지, 방풍, 오약, 빈랑, 백작약, 지각, 목향, 감초 및 길경으로 구성된 복합생약 추출물을 유효성분으로 포함하고 약제학적으로 허용 가능한 담체, 부형제 또는 희석제를 포함하는 갑상선 기능 저하증의 예방 또는 치료용 약학 조성물을 제공한다.In order to achieve the above object, the present invention is a composite herbal extract consisting of lobule, ginseng, Astragalus, Angelica, cheonggung, gyeji, hakbak, baekji, windproof, oak, betel nut, baekjak, crust, mokyang, licorice and Gilyeong as an active ingredient Provided is a pharmaceutical composition for the prevention or treatment of hypothyroidism, comprising a pharmaceutically acceptable carrier, excipient or diluent.
상기 추출물은 물, 탄소수 1 내지 4의 저급알콜 또는 이들의 혼합용매로부터 선택된 극성용매, 바람직하게는 물에 가용한 추출물을 포함한다.
The extract includes a polar solvent selected from water, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, preferably an extract available in water.
이하 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
상기 추출물은 분쇄물, 추출물 또는 그 분말엑스의 형태로 포함되는 것을 특징으로 한다. 이때, 본 발명에 따른 조성물은 상기 각 생약재의 단일 추출물을 포함하는 혼합 추출물, 또는 상기 각 생약재를 2종 이상 포함하는 식물을 함께 추출하여 제조되는 복합 추출물을 포함한다.The extract is characterized in that it is included in the form of a pulverized product, extract or powder extract thereof. At this time, the composition according to the present invention includes a mixed extract comprising a single extract of each herbal medicine, or a complex extract prepared by extracting a plant containing two or more of each herbal medicine.
본 발명에 따른 추출물은 통상의 물 추출물, 알코올 등을 용매로 한 용매 추출법 등을 적용하여 제조한 조추출물일 수 있으며, 또한 칼럼 크로마토그래피를 이용하여 정제한 분획추출물일 수 있다. 본 발명에 따른 추출물의 제조방법은 본 기술분야에 속하는 통상의 지식을 가진 자에게 알려진 추출방법을 모두 적용할 수 있으며, 예컨대 물, 알코올 또는 혼합용매에 의한 추출, 중탕이나 상온에 의한 추출법 등을 포함하나 이에 한정되지 않는다.The extract according to the present invention may be a crude extract prepared by applying a solvent extraction method using a conventional water extract, alcohol, etc. as a solvent, and may also be a fraction extract purified using column chromatography. Extraction method according to the invention can be applied to all extraction methods known to those of ordinary skill in the art, for example, extraction with water, alcohol or mixed solvents, extraction method using a bath or room temperature, etc. Including but not limited to.
본 발명의 바람직한 실시예에서는, 건조 상태의 생약들을 재료의 표면에 존재하는 이물질 등을 제거하기 위하여 세척한 다음 건조기에서 말린 후, 적절한 배합비로 혼합하고 이를 분쇄하여 생약 분쇄물을 얻을 수 있다. 또한, 상기 분말화된 복합 생약들의 1 내지 20배 부피/중량의 증류수, 탄소수 1 내지 4의 저급 알콜 또는 이들의 혼합용매, 바람직하게는 약 1 내지 20배, 가장 바람직하게는 약 3 내지 10배의 물로, 20 내지 100℃, 바람직하게는 50 내지 70℃ 추출온도에서 약 1시간 내지 10일, 바람직하게는 약 2 내지 5시간 동안 냉침, 열수추출, 초음파 추출, 환류 냉각 추출, 바람직하게는 환류 냉각 추출방법을 이용하여 수득한 추출액을 여과, 감압농축하여 물 추출물을 수득할 수 있다. In a preferred embodiment of the present invention, dried herbal medicines may be washed to remove foreign substances, etc. present on the surface of the material, and then dried in a dryer, mixed in an appropriate blending ratio, and ground to obtain the herbal powders. In addition, 1 to 20 times volume / weight of distilled water, lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, preferably about 1 to 20 times, and most preferably about 3 to 10 times With water, cold soaking, hot water extraction, ultrasonic extraction, reflux cooling extraction, preferably refluxing at 20-100 ° C., preferably at 50-70 ° C. for about 1 hour to 10 days, preferably about 2 to 5 hours. The extract obtained by using the cooling extraction method is filtered and concentrated under reduced pressure to obtain a water extract.
본 발명의 추출물은 이에 한정하는 것은 아니나, 소엽, 인삼, 황기, 당귀, 천궁, 계지, 후박, 백지, 방풍, 오약, 빈랑, 백작약, 지각, 목향, 감초 및 길경을 각 생약의 건조중량을 기준으로 1.5~4 : 0.5~1.5 : 0.5~1.5 : 0.5~1.5 : 0.5~1.5 : 0.5~1.5 : 0.5~1.5 : 0.5~1.5 : 0.5~1.5 : 0.5~1.5 : 0.5~1.5 : 0.5~1.5 : 0.5~1.5 : 0.5~1.5 : 0.5~1.5 : 0.2~1의 비율로 함유함이 바람직하다. 상기 생약 추출물들은 오랫동안 식품으로 사용되어 오던 것으로서 이로부터 추출된 본 발명의 추출물 역시 독성 및 부작용 등의 문제가 없다.
Extract of the present invention is not limited to this, leaflets, ginseng, Astragalus, Angelica, cheonggung, gyeji, bakbak, white paper, windproof, five-oak, betel nut, white peony, crust, mokyang, licorice and Giltyeong based on the dry weight of each herbal medicine 1.5 ~ 4: 0.5 ~ 1.5: 0.5 ~ 1.5: 0.5 ~ 1.5: 0.5 ~ 1.5: 0.5 ~ 1.5: 0.5 ~ 1.5: 0.5 ~ 1.5: 0.5 ~ 1.5: 0.5 ~ 1.5: 0.5 ~ 1.5: 0.5 ~ 1.5: 0.5 It is preferable to contain in the ratio of -1.5: 0.5-1.5: 0.5-1.5: 0.2-1. The herbal extracts have been used as food for a long time as the extract of the present invention extracted therefrom also has no problems such as toxicity and side effects.
상기 방법에 의해 제조된 복합생약 추출물을 장기간 갑상선 기능 항진증을 진단받고 갑상선 기능 조절을 위해 투약받고 있는 환자에게 복용시킨 결과, 안구돌출증상, 갑상선 비대, 부정맥 등의 증상을 완화시킨다.
The herbal extract prepared by the above method is administered to a patient diagnosed with hyperthyroidism for a long time and is administered for thyroid function control, thereby alleviating symptoms such as exophthalmos, hyperthyroidism, and arrhythmia.
본 발명은 상기 소엽, 인삼, 황기, 당귀, 천궁, 계지, 후박, 백지, 방풍, 오약, 빈랑, 백작약, 지각, 목향, 감초 및 길경으로 구성된 복합 생약추출물을 유효성분으로 포함하고 약제학적으로 허용 가능한 담체, 부형제 또는 희석제를 포함하는 갑상선 기능 저하증의 예방 또는 치료용 약학 조성물을 제공한다. The present invention comprises a composite herbal extract consisting of the lobule, ginseng, Astragalus, Angelica, cheongung, gyeji, thick, white paper, windproof, oak, betel nut, baekjak, crust, mokyang, licorice and gilyeong as an active ingredient and pharmaceutically acceptable Provided is a pharmaceutical composition for preventing or treating hypothyroidism, including a possible carrier, excipient, or diluent.
본 발명의 갑상선 기능 저하증의 예방 또는 치료용 약학조성물은 조성물 총 중량에 대하여 상기 추출물을 0.01 내지 50 중량%로 포함한다. The pharmaceutical composition for preventing or treating hypothyroidism of the present invention comprises 0.01 to 50% by weight of the extract based on the total weight of the composition.
본 발명의 추출물의 약학적 투여 형태는 이들의 약학적 허용 가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아 니라 적당한 집합으로 사용될 수 있다. Pharmaceutical dosage forms of the extracts of the present invention may be used in the form of their pharmaceutically acceptable salts, or may be used alone or in combination with other pharmaceutically active compounds, as well as in a suitable collection.
본 발명에 따른 추출물을 포함하는 약학조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 추출물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.
Pharmaceutical compositions comprising extracts according to the invention, in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterile injectable solutions, respectively, according to conventional methods. Can be formulated and used. Carriers, excipients and diluents that may be included in the composition comprising the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid preparations may include at least one excipient such as starch, calcium carbonate and sucrose in the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서, 본 발명의 추출물 또는 화합물은 1일 10 내지 2000 mg/kg으로, 바람직하게는 100 내지 1000 mg/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수 있다. 본 발명의 약학 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 주사에 의해 투여될 수 있다. Preferred dosages of the extracts of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the extract or compound of the present invention is preferably administered at 10 to 2000 mg / kg, preferably at 100 to 1000 mg / kg. Administration may be administered once a day or may be divided several times. The pharmaceutical composition of the present invention can be administered to various mammals such as rats, mice, livestock, humans, and the like. All modes of administration can be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular injections.
본 발명의 복합생약 추출물은 독성 및 부작용은 거의 없으므로 예방 목적으로 장기간 복용시에도 안심하고 사용할 수 있는 약제이다.
Complex herbal extract of the present invention is a drug that can be used with confidence even when taken for a long time for the purpose of prevention because there is little toxicity and side effects.
본 발명은 갑상선 기능 저하증의 예방효과를 나타내는 소엽, 인삼, 황기, 당귀, 천궁, 계지, 후박, 백지, 방풍, 오약, 빈랑, 백작약, 지각, 목향, 감초 및 길경으로 구성된 복합 생약추출물을 유효성분으로 포함하고 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 건강기능식품을 제공한다. 본 발명의 건강기능식품은 정제, 캡슐제, 환제 또는 액제 등의 형태를 포함한다. The present invention is a composite herbal extract consisting of leaflets, ginseng, Astragalus, Angelica, cheonggung, gyeji, hakbak, white paper, windbreak, oak, betel nut, white peony, crust, neck scent, licorice and Giltyeong, showing the prevention effect of hypothyroidism. It provides a dietary supplement comprising a food supplement containing a food supplement acceptable. The dietary supplement of the present invention includes the form of tablets, capsules, pills or liquids.
또한, 소엽, 인삼, 황기, 당귀, 천궁, 계지, 후박, 백지, 방풍, 오약, 빈랑, 백작약, 지각, 목향, 감초 및 길경으로 구성된 복합 생약추출물은 갑상선 기능 저하증의 예방을 목적으로 식품 또는 음료에 첨가될 수 있는데, 식품 종류는 특히 한정되는 것은 아니고, 예를 들어, 과자류, 빵류, 면류 등과 같은 각종 식품류, 물, 청량음료, 과실음료 등의 드링크류, 껌, 차, 비타민 복합제, 조미료류, 건강기능 식품류 등이 있다. 이때, 식품 또는 음료 중의 상기 추출물 또는 화합물의 양은, 일반적으로 본 발명의 건강기능식품 조성물의 경우는 전체 식품 중량의 0.01 내지 15 중량%, 바람직하게는 0.1 내지 5 중량%로 가할 수 있으며, 건강 음료 조성물에는 100㎖를 기준으로 0.01~30g, 바람직하게는 0.1~1g의 비율로 가할 수 있다. 이와 같이 하여 얻어지는 본 발명의 건강기능식품은, 본 발명의 조성물을 함유하고 있기 때문에, 본 발명의 화합물이 지닌 보건예방효과 및 보건 치료 효과를 충분히 활용할 수 있는 식품이다. In addition, the compound herbal extract consisting of leaflets, ginseng, Astragalus, Angelica, celestial organs, ginseng, thick pepper, white paper, windproof, oak, betel nut, white pear, crust, neck, licorice, and gil dynasty is a food or beverage for the purpose of preventing hypothyroidism. The food type is not particularly limited, and for example, various foods such as sweets, breads, noodles, and the like, drinks such as water, soft drinks, fruit drinks, gums, teas, vitamin complexes, seasonings, etc. And dietary supplements. At this time, the amount of the extract or compound in the food or beverage, in general, in the case of the health functional food composition of the present invention can be added to 0.01 to 15% by weight, preferably 0.1 to 5% by weight of the total food weight, health drink The composition may be added at a ratio of 0.01 to 30 g, preferably 0.1 to 1 g based on 100 ml. Since the health functional food of this invention obtained in this way contains the composition of this invention, it is a food which can fully utilize the health prevention effect and health treatment effect which the compound of this invention has.
본원에서 정의되는 식품보조첨가제는 당업계에 통상적인 식품첨가제, 예를 들어 향미제, 풍미제, 착색제, 충진제, 안정화제 등을 포함하며 하기에 예시한다.Food supplement additives as defined herein include food additives customary in the art, such as flavorings, flavoring agents, colorants, fillers, stabilizers, and the like, and are exemplified below.
본 발명의 건강 음료 조성물은 지시된 비율로 필수 성분으로서 상기 추출물 또는 화합물을 함유하는 외에는 액체성분에는 특별한 제한점은 없으며 통상의 음료와 같이 여러가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리스리 톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제 (타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등), 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100㎖ 당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g이다.The health beverage composition of the present invention has no particular limitation on the liquid component except for containing the extract or compound as essential ingredients in the indicated proportions, and may contain various flavors or natural carbohydrates, etc. as additional ingredients, like ordinary beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example rebaudioside A, glycyrrhizin, etc.), and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1-20g, preferably about 5-12g per 100ml of the composition of the present invention.
본 발명의 식품은 기재로 되는 식품의 제조공정 중에 상술한 본 발명의 조성물을 첨가하는 공정을 가함으로써 혹은 기재로 되는 식품의 제조 후에 상술한 본 발명의 조성물을 첨가하는 공정을 가함으로써 용이하게 얻을 수 있다. 이때 필요에 따라 맛과 냄새 교정제를 첨가하여도 좋다. The food of this invention is easily obtained by adding the process of adding the composition of this invention mentioned above to the manufacturing process of the base food, or by adding the process of adding the composition of this invention mentioned above after manufacture of the foodstuff which is a base material. Can be. At this time, a taste and odor correction agent may be added as needed.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.
In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
이하, 본 발명을 실시예 및 실험예에 의해 상세히 설명한다. Hereinafter, the present invention will be described in detail by Examples and Experimental Examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 한정되는 것은 아니다.
However, the following Examples and Experimental Examples are only illustrative of the present invention, and the content of the present invention is not limited to the following Examples and Experimental Examples.
실시예 1. 복합 생약 추출물의 제조Example 1. Preparation of Complex Herbal Extract
경동시장에서 구입한 소엽, 인삼, 황기, 당귀, 천궁, 계지, 후박, 백지, 방풍, 오약, 빈랑, 백작약, 지각, 목향, 감초 및 길경을 정선하여 세절한 후, 건조된 소엽 12g, 인삼, 황기, 당귀, 천궁, 계지, 후박, 백지, 방풍, 오약, 빈랑, 백작약, 지각, 목향, 감초 각 4g 및 길경 2g을 물 2 ℓ에 함께 첨가하고, 환류냉각기를 이용하여 수욕상에서 3시간씩 3회 추출하였다. 상기 추출물을 여과지에서 여과한 다음 감압농축하여 19.8 g (수율 28.3%)의 물추출물을 얻어 시료로 사용하였다.
12g, ginseng, dried leaf, ginseng, rhubarb, donkey, cheongung, gyeji, hubak, white paper, windproof, oak, betel nut Astragalus, Angelica, Cheongung, Cheongji, Thuak, White Paper, Windproof, Yakja, Betel, Count, Peony, Crust, Mokyang, Licorice each 4g and 2g of Gilyeong are added together to 2L of water, and 3 hours each on a water bath using a reflux condenser. Extracted once. The extract was filtered on a filter paper and then concentrated under reduced pressure to obtain a water extract of 19.8 g (yield 28.3%) to be used as a sample.
실험예 1. 임상실험Experimental Example 1. Clinical Experiment
1-1. 30세의 여성 : 1년 전에 출산을 경험한 후부터 갑상선 기능 항진증을 진단받고 병원에서 투약을 받고 있으나, 안구돌출, 숨참 증세, 몸의 떨림 증상, 가슴 두근거림의 증상을 호소하는 환자에게 본 발명의 실시예 1의 복합생약 추출물을 20일간 복용시킨 결과, 상기와 같은 증상들이 완화됨을 확인하였다.
1-1. 30-year-old woman who had been diagnosed with hyperthyroidism since 1 year ago and had been treated at the hospital, but complained of exophthalmos, shortness of breath, tremors, and palpitations of the present invention. As a result of taking the combined herbal extract of Example 1 for 20 days, it was confirmed that the above symptoms were alleviated.
1-2. 40세의 여성 : 밤알크기 정도의 종양이 만져지는 갑상선종을 앓고 있는 환자에게 본 발명의 실시예 1의 복합 생약 추출물을 40일간 복용시킨 결과, 갑상선종의 크기가 줄어듬을 확인하였다.
1-2. 40-year-old woman: a patient suffering from a goiter with a chestnut-like tumor touched for 40 days with the herbal extract of Example 1 of the present invention, the size of the goiter was confirmed to be reduced.
1-3. 22세의 여성 : 2년 전부터 갑상선 중독증을 앓고 있으며, 갑상선이 종대되고, 안구돌출, 심계항진, 정신흥분증이 있는 환자에게 본 발명의 실시예 1의 복합 생약 추출물을 40일간 복용시킨 결과, 안구 돌출이 완화되고, 종대된 갑상선이 감소되고, 상기의 증상들이 사라짐을 확인하였다.
1-3. 22-year-old woman: Twenty years ago, a patient with thyroid poisoning, thyroid enlargement, exophthalmos, palpitations, and psychotic irritation who took the complex herbal extract of Example 1 of the present invention for 40 days. This was alleviated, the enlarged thyroid gland was reduced and the above symptoms disappeared.
실험예 2. 독성시험Experimental Example 2. Toxicity Test
상기 실시예 1의 추출물의 랫트에 대한 경구투여에 의한 독성 존재 유무를 조사하기 위하여 SD계통의 웅성 및 자성 랫트에 각각 1 g/kg, 2 g/kg 및 5 g/kg 3개의 투여용량으로 5마리씩 단회 경구투여하고 14일간의 사망예, 일반증상, 체중변화 및 부검소견을 관찰하였다. 이와 같이 시험한 결과는 다음과 같다.In order to investigate the presence or absence of toxicity by the oral administration of the extract of Example 1 to the rat male and female rats of the 1 g / kg, 2 g / kg and 5 g / kg three doses of 5 The animals were orally administered once and observed for 14 days of death, general symptoms, weight change and autopsy findings. The result of this test is as follows.
(1) 시험 기간 중 본 발명의 조성물의 모든 투여군에서 시험 전기간동안 관찰시 사망예는 없었으며, 대조군에 비해 특이적으로 관찰된 일반증상의 변화도 없었다.(1) There were no deaths observed during the entire test period in all administration groups of the composition of the present invention during the test period, and there was no change in general symptoms specifically observed compared to the control group.
(2) 체중변화는 5 g/kg 용량군에서 투여 후 3일째에서 유의성있는 체중 감소를 나타내었을 뿐 그외 모든 투여군에서 대조군과 차이가 없었다.
(2) Body weight change showed significant weight loss on day 3 after administration in 5 g / kg dose group, but was not different from control group in all other administration groups.
이상의 결과로 보아 모든 시험물질 투여군에서 사망예 및 대조군에 비해 특이한 임상증상이 관찰되지 않았으며 체중변화 및 부검시 해부학적 소견에서도 특이한 증상은 거의 관찰되지 않았다. 또한 상기 조성물은 5 g/kg 이하의 용량에서는 뚜렷한 독성이 나타나지 않았으므로 경구투여에 의한 랫트에서의 LD50(lethal dose)은 5 g/kg 이상인 것으로 판단된다.
As a result, no clinical symptoms were observed in all the test substance-treated groups compared to the death and control groups, and there were almost no specific symptoms in the anatomical changes at the time of body weight and autopsy. In addition, since the composition did not show a clear toxicity at the dose of 5 g / kg or less, LD 50 (lethal dose) in rats by oral administration is determined to be more than 5 g / kg.
하기의 상기 약학적 제제의 제제예를 설명하나, 이는 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.
Hereinafter, the formulation examples of the pharmaceutical preparations will be described, which are intended to explain in detail only, not to limit the present invention.
제제예 1. 주사제의 제조Formulation Example 1 Preparation of Injection
실시예 1의 추출물....... ....................1.0㎎Extract of Example 1 ............................ 1.0 mg
소디움 메타비설파이트........................3.0㎎Sodium metabisulfite ........ 3.0mg
메틸파라벤...................................0.8㎎Methylparaben ............... 0.8 mg
프로필파라벤.................................0.1㎎Propylparaben ...................... 0.1 mg
주사용 멸균증류수...........................적량Sterile distilled water for injection ..............
상기의 성분을 혼합하고 통상의 방법으로 2㎖로 한 후, 2㎖ 용량의 앰플에 충전하고 멸균하여 주사제를 제조한다.
The above ingredients are mixed and made into 2 ml by a conventional method, and then filled into 2 ml ampoules and sterilized to prepare an injection.
제제예 2. 정제의 제조Formulation Example 2 Preparation of Tablet
실시예 1의 추출물...........................20㎎Extract of Example 1 ...................................... 20 mg
유당........................................100㎎Lactose 100 mg
전분........................................100㎎ Starch .............................. 100 mg
스테아린산 마그네슘.........................적량Magnesium Stearate ...............
상기의 성분을 혼합하고 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.
The above components are mixed and tableted according to a conventional method for producing tablets to produce tablets.
제제예 3. 캡슐제의 제조Formulation Example 3 Preparation of Capsule
실시예 1의 추출물...........................10㎎Extract of Example 1 ............................ 10 mg
유당........................................50㎎Lactose 50 mg
전분........................................50㎎Starch ........................................ 50 mg
탈크........................................2㎎Talc ........................................ 2mg
스테아린산마그네슘......................... 적량Magnesium Stearate ...............
상기의 성분을 혼합하고 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.
Capsules are prepared by mixing the above ingredients and filling into gelatin capsules according to a conventional method for preparing capsules.
제제예 4. 액제의 제조Formulation Example 4 Preparation of Liquid
실시예 1의 추출물...........................100㎎Extract of Example 1 .................. 100 mg
설탕........................................20gSugar .................................. 20g
이성화당....................................20gIsomerized sugar ......................................... 20 g
레몬향......................................적량Lemon Flavor ......................
정제수를 가하여 전체........................100㎖Purified water is added to the whole ........... 100ml
상기의 성분을 통상의 액제의 제조방법에 따라서 혼합하고 100㎖의 갈색병에 충전하고 멸균시켜서 액제를 제조한다.
The above components are mixed according to a conventional method for preparing a liquid, filled into a 100 ml brown bottle, and sterilized to prepare a liquid.
제제예 5. 건강 식품의 제조Formulation Example 5 Preparation of Healthy Food
실시예 1의 추출물............................1000 ㎎Extract of Example 1 ...................................... 1000 mg
비타민 혼합물................................적량Vitamin Mixture ......................
비타민 A 아세테이트.........................70 ㎍Vitamin A Acetate ......... 70 μg
비타민 E...................................1.0 ㎎Vitamin E ................................... 1.0 mg
비타민 B1.................................0.13 ㎎Vitamin B 1 ................................. 0.13 mg
비타민 B2.................................0.15 ㎎Vitamin B 2 ................................. 0.15 mg
비타민 B6..................................0.5 ㎎Vitamin B 6 ....................... 0.5 mg
비타민 B12.................................0.2 ㎍Vitamin B 12 ................................. 0.2 μg
비타민 C....................................10 ㎎Vitamin C ......................................... 10 mg
비오틴......................................10 ㎍Biotin ......................................... 10 μg
니코틴산아미드.............................1.7 ㎎Nicotinamide ........................................ 1.7 mg
엽산........................................50 ㎍Folic acid ......................................... 50 ㎍
판토텐산 칼슘..............................0.5 ㎎Calcium Pantothenate ......................................... 0.5 mg
무기질 혼합물...............................적량Inorganic mixtures ...............
황산제1철................................1.75 ㎎Ferrous Sulfate ......... 1.75 mg
산화아연.................................0.82 ㎎ Zinc Oxide ..... 0.82 mg
탄산마그네슘.............................25.3 ㎎Magnesium Carbonate ............... 25.3 mg
제1인산칼륨................................15 ㎎Potassium monophosphate ......................................... 15 mg
제2인산칼슘................................55 ㎎Dibasic calcium phosphate ............ 55 mg
구연산칼륨.................................90 ㎎Potassium Citrate ..... 90 mg
탄산칼슘..................................100 ㎎Calcium Carbonate ... 100 mg
염화마그네슘.............................24.8 ㎎Magnesium Chloride ............... 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.
Although the composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. The granules may be prepared and used for preparing a health food composition according to a conventional method.
제제예 6. 건강 음료의 제조Formulation Example 6 Preparation of Healthy Drink
실시예 1의 추출물...........................1000 ㎎Extract of Example 1 ..................... 1000 mg
구연산......................................1000 ㎎Citric Acid .................................... 1000 mg
올리고당.....................................100 gOligosaccharide ........................... 100 g
매실농축액.....................................2 gPlum concentrate ........................... 2 g
타우린.........................................1 gTaurine ......................................... 1 g
정제수를 가하여...........................전체 900 ㎖Purified water is added .............. 900 ml total
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다. After mixing the above components in accordance with a conventional healthy beverage production method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and then refrigerated and stored in the present invention For the preparation of healthy beverage compositions.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용 용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.
Although the composition ratio is a composition suitable for a preferred beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, use purpose.
본 발명의 소엽, 인삼, 황기, 당귀, 천궁, 계지, 후박, 백지, 방풍, 오약, 빈랑, 백작약, 지각, 목향, 감초 및 길경으로 구성된 복합생약 추출물은 갑상선 기능 항진증에 의해 유발되는 안구돌출, 갑상선 비대, 부정맥 등의 증상을 완화시키는 바, 갑상선 기능 항진증의 예방 또는 치료용 약학 조성물 및 건강기능식품으로 유용하게 사용될 수 있다.The herbal extract of the present invention consisting of leaflets, ginseng, Astragalus, Angelica, celestial organs, gyeji, thick, white paper, windproof, oak, betel nut, white baekjak, crust, neck, licorice and Giltyeong extract of the eye caused by hyperthyroidism, To reduce the symptoms of hyperthyroidism, arrhythmia and the like, it can be usefully used as a pharmaceutical composition and health functional food for the prevention or treatment of hyperthyroidism.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040079405A KR20060030575A (en) | 2004-10-06 | 2004-10-06 | Pharmaceutical composition comprising the complex crude drug extract for preventing and treating hyperthyroidism |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040079405A KR20060030575A (en) | 2004-10-06 | 2004-10-06 | Pharmaceutical composition comprising the complex crude drug extract for preventing and treating hyperthyroidism |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20060030575A true KR20060030575A (en) | 2006-04-11 |
Family
ID=37140542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040079405A KR20060030575A (en) | 2004-10-06 | 2004-10-06 | Pharmaceutical composition comprising the complex crude drug extract for preventing and treating hyperthyroidism |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20060030575A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102920837A (en) * | 2012-10-31 | 2013-02-13 | 侯明晓 | Traditional Chinese medicine for treating arrhythmia and preparation process and application thereof |
CN104940584A (en) * | 2015-05-26 | 2015-09-30 | 首都医科大学附属北京中医医院 | Medicinal composition for treating tachyarrhythmia as well as preparation and preparation method thereof |
CN105012705A (en) * | 2014-04-23 | 2015-11-04 | 谭杨照 | Medicine for treating hyperthyroidism |
CN105343617A (en) * | 2015-12-01 | 2016-02-24 | 李朝彬 | Traditional Chinese medicine composition for treating hyperthyroidism |
KR20200113993A (en) * | 2019-03-27 | 2020-10-07 | 김형준 | Oriental medicine composition effective for thyroid hormone level normalization |
-
2004
- 2004-10-06 KR KR1020040079405A patent/KR20060030575A/en not_active Application Discontinuation
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102920837A (en) * | 2012-10-31 | 2013-02-13 | 侯明晓 | Traditional Chinese medicine for treating arrhythmia and preparation process and application thereof |
CN105012705A (en) * | 2014-04-23 | 2015-11-04 | 谭杨照 | Medicine for treating hyperthyroidism |
CN104940584A (en) * | 2015-05-26 | 2015-09-30 | 首都医科大学附属北京中医医院 | Medicinal composition for treating tachyarrhythmia as well as preparation and preparation method thereof |
CN105343617A (en) * | 2015-12-01 | 2016-02-24 | 李朝彬 | Traditional Chinese medicine composition for treating hyperthyroidism |
KR20200113993A (en) * | 2019-03-27 | 2020-10-07 | 김형준 | Oriental medicine composition effective for thyroid hormone level normalization |
US11478523B2 (en) | 2019-03-27 | 2022-10-25 | Hyong Jun Kim | Oriental medicine composition effective for thyroid hormone level normalization |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0973529B1 (en) | Essential oil composition | |
KR100574097B1 (en) | Functional food compositions having the effect on eliminating an alcoholic hangover and improvement of liver function | |
KR100980819B1 (en) | The composition comprising complex herbal extract as an active ingredient and the preparation method thereof | |
CN102326643A (en) | Health-care tea | |
KR20080057368A (en) | A composition comprising the extract of complex herb improving liver cirrhosis, cytotoxicity and liver injury for preventing and treating of liver disease | |
KR20120026992A (en) | Compositon with anti-obesity and anti-diabetic activity comprising cudrania tricuspidata and adlay, and use thereof | |
CN105454576A (en) | Jasmine-flower-comprising assorted Chinese herbal tea and preparation method thereof | |
CN102273679A (en) | Preparation method of beverage | |
KR102192573B1 (en) | Composition for preventing and improving menstrual pain and skin troubles | |
CN101172155A (en) | Novel dosage forms of pulse-activating gallbladder warming soup and method of preparing the same | |
KR20160000695A (en) | Herbal-medicine containing dha for recovering fatigue and enhancing memory, and method of manufacturing the same | |
TW202330006A (en) | Composition for preventing, improving or alleviating symptoms relating to qi deficiency and/or blood deficiency | |
KR20060030575A (en) | Pharmaceutical composition comprising the complex crude drug extract for preventing and treating hyperthyroidism | |
CN110538308B (en) | Traditional Chinese medicine composition for hair growth and preparation method thereof | |
KR20050004950A (en) | Composition comprising the herbal complex extract for prevention and treatment of menorrhalgia and dysmenorrhea | |
CN108813500B (en) | Health-preserving honey paste with effects of tonifying middle-jiao and Qi, nourishing blood and soothing nerves and regulating human body functions | |
CN104983899A (en) | Traditional Chinese medicine composition for treating female deficiency of qi and blood | |
CN105169149A (en) | Traditional Chinese medicine composition for treating pyrophlegm stasis accumulation type thyroid cancer, preparation method and application | |
KR102217732B1 (en) | Composition for preventing and improving the development of premature pseudo-breast | |
CN104840686A (en) | Blood-pressure reduction type health-care tea | |
KR100638344B1 (en) | Composition comprising the crude drug extract for improving eye symptoms of VDT syndrome | |
CN104258224A (en) | Schisandra chinensis oral solution for treating lung-and-kidney yin-deficiency type chronic bronchitis and preparation method thereof | |
KR20040041235A (en) | Pharmaceutical composition comprising the water-soluble component of kupferkies and the extract of crude drug effective to treat neuronal paralysis and neuralgia | |
CN114712466B (en) | Medicine with weight-reducing and beautifying effects and preparation method thereof | |
CN107485698A (en) | A kind of Chinese medicine composition and preparation method thereof with blood nourishing acupuncture-stimulating, maintaining beauty and keeping young |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |